Fever is an uncommon finding during the preparative regimen of SCT.
1,2 Nevertheless, we observed that some of our patients, mainly those who received shorter infusions of high-dose etoposide, developed fever a few hours later, and this led us to suspect and rule out infectious complications.
Etoposide is a frequently used drug in different schedules for different malignancies and, when conventional doses are administered, fever is not a commonly observed adverse effect.
We retrospectively reviewed the records of our SCT patients receiving etoposide in order to find out the incidence and characteristics of this self-limited febrile syndrome. We included in the analysis a control group receiving a BU-containing regimen without etoposide, to discriminate whether BU itself played any role in this reaction.
Among 261 pediatric SCT recipients registered on our database from 1989 to 2006, we identified 61 children who had received etoposide as part of their conditioning regimen. In 41 of them, a single dose, 30-40 mg per kg of etoposide, had been administered in a short (4 h) i.v. infusion as part of BU-CY-etoposide or TBI-CY schedules. The drug had been infused pure, in parallel with saline solution, to preserve its chemical stability. Other schedules included lower doses of etoposide in longer infusions.
The control group consisted of 86 children who received BU-melphalan (n ¼ 39), BU-CY (n ¼ 22) or BU-melphalan-thiotepa (n ¼ 25).
Primary diagnoses in our study group were acute leukemia in 39 patients (95.1%), lymphoma (one child) and solid tumor (one patient). Thirty-two children (78%) were transplanted in first CR, four in second CR and four in relapse. Autologous SCT was performed in 26 children (63.4%). Sixty-one percent of children receiving high doses of etoposide presented with fever on the day of infusion (day 4 of SCT), versus 15% after other etoposide regimens or 11% after non-etoposide-containing regimens (Po0.001, w 2 ). Moreover, 71% of children had associated C-reactive protein increase (over 40 mg/l) and deranged liver function tests (aspartate aminotransferase or alanine aminotransferase higher than 40 UI/l), differing significantly (Po0.001, w 2 ) from other transplanted patients (Table 1) . Fever was moderate (median 38.8 1C, range 38-40.8) in most cases, as was C-reactive protein increase (62.1; (40-428) mg/l) and alanine aminotransferase disturbance (162.7 (40-671) UI/l). Other biochemical markers such as lactate dehydrogenase, a˜-glutamyl transpeptidase, bilirubin, creatinine, electrolytes, blood gases or prothrombin activity were normal in both groups.
Nineteen cases started on antibiotics, although bacteriemia was only documented in one febrile child (Salmonella sp.). One case of afebrile bacteriemia (Pseudomonas sp.) was also recorded. None of them died and no other infectious complications during the conditioning period were found. Symptoms always resolved, lasting less than 48 h in every case, regardless of the use of antimicrobial therapy, as is shown in Figure 1 .
In the SCT setting, fever is a sensitive but not specific sign of infection which may be related to drugs, biological therapies such as MoAb, cytokine release, transfusions, engraftment, GVHD and viral, fungal or bacterial infections. 3, 4 Bacterial systemic inflammatory response syndrome is the most common early infectious complication; nevertheless, it is infrequent during preparative regimen. Creactive protein has proven to be useful in discriminating between viral and bacterial or fungal infections, 5, 6 although other inflammatory backgrounds accompanying SCT may alter its specificity. 7 We describe a series of children with systemic inflammatory response syndrome related to the use of etoposide. We emphasize the prevalence of these symptoms after highdose short infusions, occurring in more than 60% of patients, 4 days before stem cell infusion, when neutropenia was not present yet. In all cases fever was documented a few hours after completing the etoposide administration associated to moderate elevation of C-reactive protein that quickly decreased. Transient liver function tests elevation was also documented, however this finding is common during conditioning regimens and may be related to several hepatotoxic drugs such as BU. The incidence of bacterial systemic inflammatory response syndrome was very low and no patient had a fatal outcome. The high incidence of this described febrile picture associated with the low rate of documented bacterial infection led us to recommend not starting empirical antimicrobial therapy immediately. Nevertheless, a careful and exhaustive evaluation of the child's clinical condition should be performed before attributing fever to etoposide in any individual situation. We strongly recommend antimicrobial therapy if fever persists more than 24 h, or if any other impairment is found.
In conclusion, we confirmed the existence of a selflimited sepsis-mimicking syndrome a few hours after etoposide, during conditioning regimen, in most of our patients. A careful watch-and-wait policy avoided the unnecessary use of antibiotics in this setting. Figure 1 Presence of fever the day before, during and after etoposide infusion in children receiving high doses of VP-16.
